# Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

> **NCT06544109** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 98 (estimated)

## Conditions studied

- Acute Promyelocytic Leukemia

## Interventions

- **DRUG:** venetoclax

## Key facts

- **NCT ID:** NCT06544109
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-08-01
- **Primary completion:** 2025-08-01
- **Final completion:** 2028-08-01
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06544109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06544109, "Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06544109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*